83648-77-5

Basic information

• Product Name: 2-<4-(cis-2-hydroxycyclopentylmethyl)phenyl>propionic acid
• CAS NO: 83648-77-5
• Molecular Weight: 248.322
• Mol File: 83648-77-5.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 2-<4-(cis-2-hydroxycyclopentylmethyl)phenyl>propionic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-<4-(cis-2-hydroxycyclopentylmethyl)phenyl>propionic acid(83648-77-5)
• EPA Substance Registry System: 2-<4-(cis-2-hydroxycyclopentylmethyl)phenyl>propionic acid(83648-77-5)

Safety Data

• Hazardous Substances Data: 83648-77-5(Hazardous Substances Data)

Upstream product

• 89631-57-2 methyl (+/-)-2-<4-(trans-2-hydroxycyclopentylmethyl)phenyl>propionate 
• 89631-57-2 methyl (+/-)-2-<4-(cis-2-hydroxycyclopentylmethyl)phenyl>propionate 
• 89631-53-8 methyl 2-<4-(cis-2-acetoxycyclopentylmethyl)phenyl>propionate 
• 90319-78-1 (2S)-2-<4-((1S)-2-oxocyclopentylmethyl)phenyl>propionic acid 
• 68767-14-6 loxoprofen 

Downstream Products

• 88378-29-4 {2-[4-((1R,2S)-2-Acetoxy-cyclopentylmethyl)-phenyl]-propionylamino}-acetic acid ethyl ester 
• 88378-26-1 2-{2-[4-((1S,2R)-2-Hydroxy-cyclopentylmethyl)-phenyl]-propionylamino}-ethanesulfonic acid 
• 88378-27-2 {2-[4-((1S,2R)-2-Hydroxy-cyclopentylmethyl)-phenyl]-propionylamino}-acetic acid 
• 88378-28-3 2-[4-((1R,2S)-2-Acetoxy-cyclopentylmethyl)-phenyl]-propionic acid 
• 89631-57-2 methyl (+/-)-2-<4-(cis-2-hydroxycyclopentylmethyl)phenyl>propionate 
• 89631-57-2 methyl (+/-)-2-<4-(trans-2-hydroxycyclopentylmethyl)phenyl>propionate 

Relevant articles and documents

HR1405-01, a Safe intravenous NSAID with superior anti-inflammatory and analgesic activities in preclinical trials

Combinational utilization of intravenous non-steroidal anti-inflammatory drugs (NSAIDs) with opium analgesic is an effective alternative modality for pain control after surgery. This regimen is known for reducing the risk of addiction induced by opium analgesic. However, current intravenous NSAIDs have solubility problems, limiting their clinical applications. Although loxoprofen exhibits strong anti-inflammatory and analgesic activities with relatively low ulcerogenicity, its relatively low bioavailability makes it not an ideal drug candidate for intravenous injection. We selected the bioactive metabolite (6) of loxoprofen as a candidate and developed a new intravenous NSAID, HR1405–01. This metabolite exhibited significantly stronger anti-inflammatory and analgesic activities than parecoxib sodium injection or ibuprofen injection. The excellent potency and solubility of HR1405–01 allowed the avoidance of utilization of cosolvent in the formulation, resulting in fewer side effects and a better safety profile. Therefore, HR1405–01 might be a promising candidate for the development of a new intravenous NSAID.

Evaluation of loxoprofen and its alcohol metabolites for potency and selectivity of inhibition of cyclooxygenase-2

Loxoprofen, its trans-alcohol and cis-alcohol metabolites were evaluated for selectivity of inhibition of COX-2 over COX-1. The (2S,1′R,2′S)- trans-alcohol derivative was found to be the most active metabolite and to be a potent and nonselective inhibitor of COX-2 and COX-1 in both enzyme and human whole blood assays.

Structural determination of rat urinary metabolites of sodium 2-[4-(2-oxocyclopentylmethyl)phenyl]propionate dihydrate (loxoprofen sodium), a new anti-inflammatory agent

-